Introduction

Joint wear can cause persistent pain and limited movement, and cartilage has a limited ability to heal itself. If you are weighing up non-surgical options, ChondroFiller is one of the more biologically active choices available. This article explains, in plain terms, how the injection is thought to work and what realistic expectations look like.

What ChondroFiller Is

ChondroFiller is a Class III CE-marked medical device: a cell-free, type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. It is delivered as an ultrasound-guided outpatient injection — no theatre, no incision, no general anaesthetic. The device self-gels within approximately three to five minutes of being placed, filling the contours of the worn surface.

Because it is cell-free, it introduces no foreign cells. Instead, the collagen matrix acts as a chemotactic scaffold, attracting the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect. Over time, those recruited cells are intended to differentiate and deposit new cartilage-like tissue as the scaffold is gradually resorbed.

How the Injection Works in the Joint

Once injected, the gel settles over worn or damaged cartilage surfaces, creating a protective, cushioning layer that may reduce the grinding between joint surfaces. Working in this way, it is best understood as a biologically supportive, joint-preserving intervention rather than a simple pain-masking agent.

The collagen matrix mimics the native extracellular matrix, providing a structural environment that supports cell adhesion, migration, and chondrogenic differentiation. The scaffold's adhesiveness allows it to remain in place without sutures or additional fixatives. Patient positioning during injection is important: the treated surface should be horizontal to prevent the gel from draining before it sets.

What the Evidence Suggests

Many patients report improved movement and less pain, though individual responses vary and benefits cannot be guaranteed. A 2023 study of an acellular collagen matrix injection for thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength (Corain et al., Cartilage, 2023). In the knee, published series report International Knee Documentation Committee (IKDC) scores improving by approximately 30 points over 12 to 36 months. In the hip, modified Harris Hip Scores have improved by over 30 points in reported cases. Imaging using Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scoring has shown values of around 80 and above in knee and hip studies, suggesting good-quality defect fill.

Compared with more invasive surgical alternatives such as microfracture or autologous chondrocyte implantation, the ChondroFiller injection carries a markedly lower procedural risk. It is not, however, equivalent in scope to surgical approaches for larger or load-bearing defects.

ChondroFiller Injection and Liquid Cartilage: Two Distinct Options

It is worth being clear about terminology. The ChondroFiller injection is a non-surgical, outpatient procedure suited to accessible lesions and smaller joints. Liquid Cartilage — formally the Lee Liquid Cartilage Protocol — is an entirely different, surgical pathway. It is a keyhole (arthroscopic) procedure developed by Professor Paul Y. F. Lee, in which the ChondroFiller scaffold is placed under direct vision alongside biological adjuncts such as platelet-rich fibrin or plasma and, where indicated, the patient's own mesenchymal stem cells from bone-marrow concentrate. Liquid Cartilage involves theatre, anaesthetic, and a structured rehabilitation programme; it is typically used for larger or load-bearing defects in the knee, hip, shoulder, or ankle.

The two are not synonyms. Choosing between them depends on defect size, location, joint accessibility, and individual clinical circumstances. A specialist assessment is required to determine which pathway, if either, is appropriate.

Conclusion

ChondroFiller is a non-surgical, cell-free collagen injection that works by providing a biological scaffold for the joint's own cells to populate and, in time, produce new cartilage-like tissue. It may help some people with osteoarthritis or focal cartilage wear, but it is not a cure and does not reverse arthritis. For an assessment tailored to your joint and circumstances, including whether a non-surgical injection or a surgical pathway such as Liquid Cartilage is more appropriate, a consultation at the London Cartilage Clinic can help clarify your options.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.